Speaker

Josie Gayton

Strategic Advisor Theratrop (radiopharm), Precirix

Josie Gayton, Strategic Advisor Theratrop (radiopharm) at Precirix, is speaking at 8th Targeted Radiopharmaceuticals Summit Europe 2026 (London, United Kingdom, 1–3 Dec 2026) in the session “From Discovery to First-in-Human: Navigating the Critical Preclinical Decisions That Determine Translational Success”.

Conferences: 1
Keynotes: 0
Upcoming: 1

Upcoming appearances

8th Targeted Radiopharmaceuticals Summit Europe 2026
1–3 Dec 2026London, United Kingdom
- SpeakerFrom Discovery to First-in-Human: Navigating the Critical Preclinical Decisions That Determine Translational Success
- PanelInvestor Strategy Panel: From Specialist Therapy to Standard of Care: What Must Happen for RLTs to Become a Commercially Scalable Oncology Modality?With Kemp Dolliver, Dan Squair, Kevin Madagan

More speakers at 8th Targeted Radiopharmaceuticals Summit Europe 2026

Friedmund Bachmann
Vice President CMC & Project Lead, OncoOne
Luke Brzozowski
Executive Director - Translational Research & Core Facilities ,Program Sponsor, Theranostics, UHN
Frederic Desdouits
Chief Executive Officer, OranoMed
Chaitanya Divgi
Senior Expert - Strategic Therapeutic Innovation, Novartis
Rich Edwards
Chief Technology Officer, Nuclide Therapeutics
Waisi Eng
Chief Technology Officer, Norroy North America Inc.

See all 33 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Josie Gayton, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].